TIENT JOURNEY - Order of Nurses LEB Program.pdf · Fadi El Karak Colette Hanna Abir Al Ahmadie...

8

PATIENT JOURNEY

THE 3 RD CONTIN

UOUS EDUCATION FOR

ONCOLOGY PRACTITIONERS

October 26 - 27, 2018

Hilton Habtoor Hotel, Lebanon

3 CE CREDITS CNE CREDITS

THE LEBANESE ORDEROF PHARMACISTS

you’ve gotI need everythingI don’t want a fairy tale

In advanced gastric/GEJ adenocarcinomaAdding CYRAMZA to paclitaxel significantly increased OS vs paclitaxel alone1

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28

OS

PR

OB

AB

ILIT

Y

TIME FROM RANDOMIZATION (MONTHS)

CYRAMZA+ paclitaxel

(n=330)

Placebo+ paclitaxel(n=335)

9.6MONTHS(8.5, 10.8)

7.4MONTHS

(6.3, 8.4)

1.0

0.8

0.6

0.4

0.2

0.0

CYRAMZA+ paclitaxel

Placebo+ paclitaxel

330 308 267 228 185 148 116 78 60 41 24 13 6 1 0

335 294 241 180 143 109 81 64 47 30 22 13 5 2 0

NUMBER AT RISK

CYRAMZA + paclitaxel

Placebo+ paclitaxel

CI=confidence interval; GEJ=gastroesophageal junction; HR=hazard ratio; OS=overall survival. References: 1. Wilke H, Muro K, Van Cutsem E, et al; for the RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-1235.

40 %40.1% (34.7, 45.5)

(n=330)In the placebo + paclitaxel arm

n=335), OS rate was 30.2%(25.1, 35.3) at 1 year.

1-yearOS rate

For further information about Lilly and Lilly products please contact us on the below address:Lebanon: Jisr el Wati, Sin El Fil, Fouad Ammoun Street, Plot #2252, 4th & 5th Floors, POB: 55-158, Tel: (961) 1 504 700, Fax: (961) 1 504 701

For adverse events and safety reporting, please send an email to the following email address : [email protected].

PP-R

B-LB

-001

1

CYRAMZA Summary of Product Characteristics:CYRAMZA® is a human vascular endothelial growth factor receptor 2 Antagonist indicated • as a single agent or in combination with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. • in combination with docetaxel, for treatment of metastatic nonsmall cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA.• in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. DOSE AND ADMINISTRATION: For intravenous infusion only. Do not administer as an intravenous push or bolus. Gastric Cancer• The recommended dose of CYRAMZA either as a single agent or in combination with weekly paclitaxel is 8 mg/kg every 2 weeks. Non-Small Cell Lung Cancer• Administer CYRAMZA at 10 mg/kg intravenously on day 1 of a 21-day cycle prior to docetaxel infusion. Colorectal Cancer • Administer CYRAMZA at 8 mg/kg intravenously every 2 weeks, prior to FOLFIRI administration. DOSAGE FORMS AND STRENGTHS: Injection: 100 mg/10 mL (10 mg per mL) solution, single-dose vial and 500 mg/50 mL (10 mg per mL) solution, single-dose vial. CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS • Arterial Thromboembolic Events (ATEs): Serious, sometimes fatal ATEs have been reported in clinical trials. Discontinue CYRAMZA for severe ATEs.• Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend CYRAMZA for severe hypertension. Discontinue CYRAMZA for hypertension that cannot be medically controlled. • Infusion-Related Reactions: Monitor for signs and symptoms during infusion.• Impaired Wound Healing: Withhold CYRAMZA prior to surgery.• Clinical Deterioration in Patients with Cirrhosis: New onset orworsening encephalopathy, ascites, or hepatorenal syndrome canoccur in patients with Child-Pugh B or C cirrhosis.• Reversible Posterior Leukoencephalopathy Syndrome: Discontinue CYRAMZA.• Proteinuria Including Nephrotic Syndrome: Monitor proteinuria. Interrupt CYRAMZA for urine protein levels ≥2 g/24 hours. Permanently discontinue CYRAMZA for urine protein levels>3 g/24 hours or for nephrotic syndrome. • Thyroid Dysfunction: Monitor thyroid function during treatment with CYRAMZA. • Embryofetal Risk: Can cause fetal harm. ADVERSE REACTIONS • The most common adverse reactions observed in single-agent CYRAMZA-treated patients at a rate of ≥10% and ≥2% higher than placebo were hypertension and diarrhea. • The most common adverse reactions observed in patients treated with CYRAMZA plus paclitaxel at a rate of ≥30% and ≥2% higher than placebo plus paclitaxel were fatigue, neutropenia, diarrhea, and epistaxis.• The most common adverse reactions observed in patients treatedwith CYRAMZA plus docetaxel at a rate of ≥30% and ≥2% higher than placebo plus docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation. • The most common adverse reactions observed in patients treated with CYRAMZA plus FOLFIRI at a rate of ≥30% and ≥2% higher than placebo plus FOLFIRI were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.

THE 3RD CONTINUOUS EDUCATION FOR ONCOLOGY PRACTITIONERS

PATIENT JOURNEYOctober 26 - 27, 2018 | Hilton Habtoor Hotel, Lebanon

8

Friday October 26, 2018

13:00 Registration

14:00 - 14:05 Welcoming Note Fadi Nasr

14:05 - 14:10 Flash Back CEOP 2016 - 2017

14:10 - 14:15 Barbara Nassar Association Achievement Hani Nassar

Moderator: Hampig Kourie14:15 - 14:45 Optimizing Treatment Outcome in Soft Tissue Sarcoma

Symposium Sponsored by LillyMarwan Ghosn

14:45 - 15:45 The Journey of CLL Case from a Patient PerspectiveModerator: Daisy Samaha Internal Medicine Hematology PerspectiveCytogenetic PerspectiveNurse PerspectiveClinical Pharmacy PerspectiveJourney in the HospitalFlow Cytometry

Fadi HaddadFadi NasrNadine JalekhSahar AtiehPatricia Shuhaiber Fadi G. HaddadHanadi Samaha

15:45 - 16:15 Optimizing Efficacy and Maintaining Quality of Life in Follicular LymphomaSymposium Sponsored by Roche

Fadi Nasr

16:15 - 16:35 Coffee Break Sponsored by Pfizer



8

Friday October 26, 2018

16:35 - 17:05 Reshaping the Journey of Alk and ROS-1 positive NSCLC Patients Symposium Sponsored by Pfizer

Georges Chahine

17:05 - 17:15 Psychology of CancerModerator: TBA

17:05 - 17:15 Role of Psycho-Oncology at any Stage of the Cancer Trajectory Toni Sawma

17:15 - 17:55 Immunotherapy and side effects: How can we Manage it? Symposium Sponsored by BMS

Georges Chahine

17:55 - 18:55 Seeing Multiple Myeloma Case From a Patient EyesModerator: Mouin Jammal - Elisar DagherOrthopedic PerspectiveNephrology PerspectiveHematology PerspectiveCytogenetic PerspectiveNurse PerspectiveClinical Pharmacy PerspectiveTreatment in the HospitalRadiology PerspectiveInternal Medicine Perspective

Ismat GhanemSerge FinianosFadi NasrHampig KourieSouad MaaloufMay Fakhoury - Fouad Mahfouz - Aline HajjJanah Maddah - Roland EidMarwan HaddadElie Stephan



8

Saturday October 27, 2018

08:00 Registration

09:00 - 09:45 Role of Pembrolizumab in Advanced MSI-H/dMMR Solid Cancers Symposium Sponsored by MSD

Ali Shamseddine

09:45 - 10:45 Living the Fear of a Breast Cancer Patient Moderator: Michel MattarEpidemiology Perspective Mamography Perspective Pathology Perspective Genomix Test Surgeon Perspective Treatment Discussion HER2-Negative ER/PR-PositiveTreatment Discussion ER/PR3-Negative Treatment Discussion ER/PR HER2-PositivePsychatric Perspective Hospital Perspective Radiotherapy Perspective

Salim AdibJinane SlabaAbir KhaddageGeorges ChahineDavid AtallahMarcel MassoudRita RizkMarwan GhosnKarine NassarLeony Antoun - Elsa RawadiFares Azoury

10:45 - 11:05 Coffee Break Sponsored by Sanofi

11:05 - 11:35 Kisqali: Rapid Power that Redefines First LineSymposium Sponsored by Novartis

Fadi Nasr



8

Saturday October 27, 2018

11:35 - 12:05 CDK4/6 Inhibitors and the Changes in the Management Paradigm of HR+/Her2-Advanced BreastCancer Symposium Sponsored by Pfizer

Fadi Farhat

12:05 - 13:05 Describing the Hope of a Lung Cancer PatientModerators: Youssef Haddad - Dany AbdallahPulmonary Perspective First Line Treatment Second Line Treatment EGFR Mutation-Positive ALK Positive Anatomo-Pathologie Clinical Pharmacy Perspective Nurse Perspective

Ralph Nehme - Georges DabarFadi El KarakColette HannaAbir Al AhmadieAnthony SaroufinValerie Aftimos Yasmine YaredNoha Merhe

13:05 - 13:45 Renal Cell Carcinoma: Whats New in the Front Line Treatment Paradigm?Symposium Sponsored by BMS

Joseph Kattan

13:45 - 14:00 Partnership in CareModerator: Randa Atallah

13:45 - 14:05 Patient Partnership in Care Rima Sassine Kazan

14:05 - 14:50 Role of Pembrolizumab in Non-Small Cell Lung Cancer: First Line and Second Line Treatment Fadi FarhatSymposium Sponsored by MSD

14:50 - 15:50 Lunch Break



8

Saturday October 27, 201815:50 - 16:20 Targeting Angiogenesis in mCRC Management: Optimal Treatment Sequencing

Symposium Sponsored by SanofiFadi El Karak

16:20 - 17:20 A Patient with a Colorectal Cancer StoryModerators: TBAGastroenterology Perspective Surgeon Perspective Oncologist Point of View Nurse Perspective Radiotherapy Perspective

Rana Helou - Antoine Abi AbboudHenry Bitar - Raja Wakim - Antoine KachiEvelyn HelouLoren HageGeorges Farha

17:20 - 17:40 Coffee Break

17:40 - 18:10Moderator: TBA Importance of Treatment Sequence in Gastric Cancer Symposium Sponsored by Lilly

Fadi El Karak

18:10 - 19:10 Facing the Fact of Prostate CancerModerators: TBASurgeon Perspective Clinical Pharmacy Perspective Oncologist Point of View Radiotherapy

Elie Nemr - Fouad Aoun - Antoine NjeimCarole DibJoseph KattanClement Khoury



8

Saturday October 27, 2018 (Parallel Session | Convention Center - Rabieh Room) Sponsored by Abbvie

Session 109:00 - 09:3009:30 - 09:4009:40 - 09:45

CLL Disease StateCLL Disease State (Movie)Voting Quiz

Session 209:45 - 10:1510:15 - 10:2510:25 - 10:30

Hematological MalignanciesHematological Malignancies(Movie)Voting Quiz

10:30 - 10:50 Coffee Break

Session 310:50 - 11:2011:20 - 11:25

CLL Disease StateVoting Quiz

Session 411:25 - 11:5511:55 - 12:00

CLL Treatment LandscapeVoting Quiz

Closing



8

Notes

--------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------

Organized by: 4th Floor, Qubic CenterDaoud Ammoun StreetHorsh Tabet - Sin El FilP.O. Box: 90-361 BeirutTel: +961 1 510880/1/2/3 Mobile: +961 71 103123

LEBANON UAE

|DMCC Business CentreAlmas TowerJumeirah Lakes Dubai, United Arab EmiratesUnit No: 3820Mobile: +971 50 9110475

We would like to thank the belowsponsors for their contribution to the success of its annual congress

ZALTRAP® (af l ibercept ) + FOLFIRI 2nd LINE AGAINST METASTATIC COLORECTAL CANCER (mCRC)

®

Full Prescribing Information available at Sanofi-aventis Liban SAL, Corniche El Nahr, Pierre Gemayel street, Holcom building, 2nd floorBeirut, Lebanon - P.O. Box: 11069, Phone: +961 1 44 02 20 Fax: +961 1 56 22 64

ZALTRAP, in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy, is indicated for adult patients with mCRC that is resistant to or has progressed following an oxaliplatin-containing regimen.

The most common adverse reactions (all grades, ≥ 20% incidence) reported at least 2% greater for the ZALTRAP/FOLFIRI regimen as compared to the placebo/FOLFIRI regimen in order of decreasing frequency were leucopenia, diarrhoea, neutropenia, proteinuria, increased aspartate aminotransferase (AST), stomatitis, fatigue, thrombocytopenia, increased alanine aminotransferase (ALT), hypertension, weight loss, decreased appetite, epistaxis, abdominal pain, dysphonia, increased serum creatinine, and headache. The most common reported grades 3-4 reactions (... incidence) reported at least 2% greater incidence for the ZALTRAP/FOLFIRI regimen as copared to placebo/FOLFIRI regimen in order of decreasing frequency, were neutropenia, diarrhoea, hypertension, leucopenia, stomatitis, fatigue, proteinuria, and asthenia. The most frequent adverse reactions leading to permanent discontinuation in ...1% of patients treated with the ZALTRAP/FOLFIRI regimen were vascular disorders (3.8%) includng hypertension (2.3%), infections (3.4%), asthenia/fatigue (1.6%, 2.1%), diarrhoea (2.3%), dehydration (1%), stomatitis (1.1%), neutropenia (1.1%), proteinuria (1.5%), and pulmonary embolism (1.1%)1

Reference: 1 .Zaltrap abridged prescribing information

References:1. OPDIVO® (Nivolumab) US PI, April 2018 . 2. Motzer RJ, Tannir NM, McDermott DF, et al; Checkmate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;37B(14): 1277-1290.

HIGHLIGHTS OF PRESCRIBING INFORMATION1

These highlights do not include all the information needed to use OPDIVO® safely and e�ectively. See full prescribing information for OPDIVO®.

OPDIVO® (Nivolumab) injection, for intravenous use. Initial U.S. Approval: 2014INDICATIONS AND USAGE OPDIVO® is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of: Patients with BRAF V600 wild-type unresectable or metastatic melanoma as a single agent; with BRAF V600 mutation-positive unresectable or metastatic melanoma as a single agent;a with unresectable or metastatic melanoma, in combination with ipilimumab;a with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting. Patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy, with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO®. Patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy; with intermediate or poor risk, previously untreated advanced renal cell carcinoma, in combination with ipilimumab. Adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: b autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT. Patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. Patients with locally advanced or metastatic urothelial carcinoma who: b have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.b Patients with hepatocellular carcinoma who have been previously treated with sorafenib.a DOSAGE AND ADMINISTRATION Administer as an intravenous infusion over 30 minutes. Unresectable or metastatic melanoma: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. OPDIVO® with ipilimumab: OPDIVO® 1 mg/kg, followed by ipilimumab on the same day, every 3 weeks for 4 doses, then OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. Adjuvant treatment of melanoma: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. Metastatic non-small cell lung cancer: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. Advanced renal cell carcinoma: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. OPDIVO® with ipilimumab: OPDIVO® 3 mg/kg followed by ipilimumab 1 mg/kg on the same day every 3 weeks for 4 doses, then OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. Classical Hodgkin lymphoma: OPDIVO® 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Recurrent or metastatic squamous cell carcinoma of the head and neck: OPDIVO® 240mg every 2 weeks or 480 mg every 4 weeks. Locally advanced or metastatic urothelial carcinoma: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer: OPDIVO® 240 mg every 2 weeks. Hepatocellular carcinoma: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. WARNINGS AND PRECAUTIONS Immune-mediated pneumonitis: Withhold for moderate and permanently discontinue for severe or life-threatening pneumonitis. Immune-mediated colitis: Withhold OPDIVO® when given as a single agent for moderate or severe and permanently discontinue for life-threatening colitis. Withhold OPDIVO® when given with ipilimumab for moderate and permanently discontinue for severe or life-threatening colitis. Immune-mediated hepatitis: Monitor for changes in liver function. Withhold for moderate and permanently discontinue for severe or life-threatening transaminase or total bilirubin elevation. Immune-mediated endocrinopathies: Withhold for moderate or severe and permanently discontinue for life-threatening hypophysitis. Withhold for moderate and permanently discontinue for severe or life-threatening adrenal insu¢ciency. Monitor for changes in thyroid function. Initiate thyroid hormone replacement as needed. Monitor for hyperglycemia. Withhold for severe and permanently discontinue for life-threatening hyperglycemia. Immune-mediated nephritis and renal dysfunction: Monitor for changes in renal function. Withhold for moderate or severe and permanently discontinue for life-threatening serum creatinine elevation. Immune-mediated skin adverse reactions: Withhold for severe and permanently discontinue for life-threatening rash. Immune-mediated encephalitis: Monitor for changes in neurologic function. Withhold for new-onset moderate to severe neurological signs or symptoms and permanently discontinue for immune-mediated encephalitis. Infusion reactions: Discontinue OPDIVO® for severe and life-threatening infusion reactions. Interrupt or slow the rate of infusion in patients with mild or moderate infusion reactions. Complications of allogeneic HSCT after OPDIVO®: Monitor for hyperacute graft-versus-host-disease (GVHD), grade 3-4 acute GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease, and other immune-mediated adverse reactions. Transplant-related mortality has occurred. Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of e£ective contraception. ADVERSE REACTIONS Most common adverse reactions (≥20%) in patients were: OPDIVO® as a single agent: fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, and abdominal pain. OPDIVO® with ipilimumab for melanoma: fatigue, rash, diarrhea, nausea, pyrexia, vomiting, and dyspnea. OPDIVO® with ipilimumab for renal cell carcinoma: fatigue, rash, diarrhea, musculoskeletal pain, pruritus, nausea, cough, pyrexia, arthralgia, and decreased appetite. USE IN SPECIFIC POPULATIONS Lactation: Discontinue breastfeeding.For any additional information or adverse events reporting, please contact Bristol-Myers Squibb Medical Information on http://www.globalbmsmedinfo.coma This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. b This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.aRCC=advanced renal cell carcinoma

Bristol-Myers SquibbLaboratory Complex

Dubai Science ParkP.O. Box: 454409, Dubai, UAE

Tel: +971-4-45021001506AE18PR04170-01

* intermediate- or poor-risk aRCC patients

NOW APPROVED FOR THE FIRST LINE TREATMENT OF PATIENTS WITH aRCC *1,2

®

OPDIVO® is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma, in combination with Ipilimumab1

TIENT JOURNEY - Order of Nurses LEB Program.pdf · Fadi El Karak Colette Hanna Abir Al Ahmadie...

Documents

Transcript of TIENT JOURNEY - Order of Nurses LEB Program.pdf · Fadi El Karak Colette Hanna Abir Al Ahmadie...